TORONTO, July 15, 2014 /CNW/ - The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). For eligible patients the positive impact of Metvix PDT cannot be overestimated in pre-cancerous AK (Actinic Keratoses) and superficial BCC (Basal Cell Carcinomas) treatment.
Metvix PDT delivers precisely targeted treatment for AK and BCC. Metvix PDT is changing the treatment of AK and BCC by offering patient preferred advantages:
- Clinical outcomes comparable to current standard modes of treatment
- Minimally non-invasive procedure with superior cosmetic outcomes
- Healing can take place in as little as 7-10 days as treatment is precisely directed
The Odette Cancer Centre, one of the top cancer centres in the world, consistently offers the highest level of patient care while conducting world-class research and teaching in a clinical setting. Always committed to improving treatment and patient care, the Odette Cancer Centre once again leads the way by offering Metvix PDT for NMSC. Instrumental in bringing Metvix PDT to the Centre Dr. Gregory Czarnota, senior scientist & director, Odette Cancer Research Program, Dr. Steven Babic, medical physicist, and Dr. Toni Barnes, radiation oncologist are at the forefront of this initiative that marks a new area of NMSC treatment.
The Odette Cancer Centre is ranked the 2nd largest comprehensive cancer centre in Canada and the 6th largest comprehensive cancer centre in North America, ranked among a select group of world-class institutions who engage in intense research, community outreach and who provide the full spectrum of patient care.
The partnership of Galderma and the Odette Cancer Centre reinforces the strong commitment of both parties to continue to bring the most innovative and technologically advanced treatments to improve patients' experiences and outcomes when being treated for AK and NMSC.
Galderma is a leading global pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma's important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, therapeutic skin care and aesthetic and corrective medical solutions) contribute to maintaining its strong leadership in dermatology. Galderma is committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 31 wholly-owned affiliates with a worldwide network of distributors and more than 4,000 employees.
Galderma Canada Inc. offers a product portfolio to treat a range of dermatological conditions including: acne, eczema, rosacea, psoriasis and non-melanoma skin cancer.
Strategic brands include:
Tactuo® and Differin® (acne), MetroGel® and Apprilon™ (rosacea), Clobex® (psoriasis), Metvix® (skin cancer), Cetaphil® (therapeutic skin care).
SOURCE: Galderma Canada Inc.
For further information: Contact Grant Gibson at The Gibson Group with any inquiries at 905-713-3615 x201